Depleting plasmacytoid dendritic cells reduces local type I interferon responses and disease activity in patients with cutaneous lupus.
Sci Transl Med. 2021 May 26;13(595):eabf8442. doi: 10.1126/scitranslmed.abf8442.
Sci Transl Med. 2021.
PMID: 34039741
Clinical Trial.